Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study.
Sebastian BauerMichael C HeinrichSuzanne GeorgeZalcberg JohnCesar SerranoAndré B P van KuilenburgRobin L JonesSteven AttiaGina D'AmatoPing ChiPeter ReichardtJulie MeadeYing SuRodrigo Ruiz-SotoJean Yves BlayMargaret von MehrenPatrick SchöffskiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Ripretinib provided clinically meaningful activity across mutation subgroups in patients with advanced GIST, demonstrating that ripretinib inhibits a broad range of KIT/PDGFRA mutations in patients with advanced GIST who were previously treated with three or more TKIs.